DOUGLAS RICHARD 4

What Happened
Douglas Richard, a director of Aldeyra Therapeutics, purchased 70,000 shares on 2026-03-19 at $1.40 per share, for a total reported cash outlay of $98,000. The transaction is reported on a Form 4 filed 2026-03-20 and is coded as a purchase (P), indicating an acquisition rather than a sale.

Key Details

• Transaction date: 2026-03-19; Form 4 filed: 2026-03-20.
• Transaction code: P = Purchase (open-market or private purchase per the filing).
• Price and quantity: 70,000 shares at $1.40 each; total value $98,000.
• Shares owned after transaction: not specified in the provided filing.
• Footnotes/plans: filing does not disclose a 10b5-1 plan, tax withholding, or other special footnotes.
• Timeliness: Filed the day after the trade — no late filing indicated.

Context
Insider purchases are often watched by investors as one data point about insider conviction, but they do not by themselves prove future performance. This is a modest-sized director purchase ($98K) reported promptly; no further material details (ownership level, plan-based trade, or special conditions) were disclosed in the Form 4.